Over the last few years, the infertility treatment market has witnessed significant advancements in terms of the development and commercialization of infertility treatment products. Technological advancements in infertility treatment devices; continuous decline in fertility rates; increasing public-private investments, funds, and grants; and rising number of fertility clinics worldwide are some of the major driving factors for the infertility treatment market.
In 2016, North America held the largest share of the infertility treatment market. However, emerging Asia-Pacific countries such as China, Japan, and India are considered as new revenue-generating destinations for prominent market players. Increasing medical tourism, reductions in treatment prices, growing healthcare expenditure, and increasing population (along with lifestyle changes, such as postponement of childbirth) are expected to drive growth opportunities in the Asia-Pacific region during the forecast period.
On the basis of procedure, the infertility treatment market is segmented into assisted reproductive technology (ART), artificial insemination (AI), fertility surgeries, and others. In 2016, the ART segment accounted for the largest share of the infertility treatment market, by procedure, owing to increasing infertility and rising prevalence of lifestyle disorders (leading to decline in the fertility rate), technological innovations in the field of IVF, growing adoption of procedures like surrogacy by same-sex couples, and the high success rate of ART procedures.
Based on products, the infertility treatment market is segmented into instruments, media & consumables, and accessories. The instruments market is further segmented into micromanipulators, laser systems, imaging systems, ovum aspiration pumps, sperm analyzers, incubators, workstations, and gas analyzers. Instruments accounted for the largest share of the global infertility treatment market in 2016. The large share of this segment can primarily be attributed to the application of instruments in a wide range of treatment applications.
On the basis of patient type, the infertility treatment market is segmented into male patients and female patients. In 2016, the female patients segment accounted for the largest market share, primarily due to the decreasing female fertility rates and the availability of a wide range of treatment options.
The key players in this market are focused on strengthening their position in emerging markets by adopting both organic and inorganic growth strategies. For instance, in January 2017, Genea Limited (Australia) and Merck (Germany) together opened a new Centre of Excellence for Fertility in Bangkok. Likewise, in December 2016, Cook Medical opened its South Asia Distribution Centre (SADC) in Singapore to meet the increasing product demand across India, Korea, Malaysia, Taiwan, Thailand, and Hong Kong.
